-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60

Benzinga·08/10/2026 12:01:31
Listen to the news
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $50 to $60.